|
Gene: ARHGAP36 |
Gene summary for ARHGAP36 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARHGAP36 | Gene ID | 158763 |
Gene name | Rho GTPase activating protein 36 | |
Gene Alias | ARHGAP36 | |
Cytomap | Xq26.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q6ZRI8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
158763 | ARHGAP36 | PTCwithHT_8 | Human | Thyroid | HT | 1.68e-15 | 6.73e-01 | 0.0351 |
158763 | ARHGAP36 | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.68e-08 | 7.32e-01 | 0.0381 |
158763 | ARHGAP36 | male-WTA | Human | Thyroid | PTC | 9.50e-14 | 2.77e-01 | 0.1037 |
158763 | ARHGAP36 | female-WTA | Human | Thyroid | PTC | 4.31e-10 | 6.06e-01 | 0.0726 |
158763 | ARHGAP36 | PTC04 | Human | Thyroid | PTC | 5.84e-60 | 3.10e+00 | 0.1927 |
158763 | ARHGAP36 | PTC05 | Human | Thyroid | PTC | 1.91e-04 | 5.53e-01 | 0.2065 |
158763 | ARHGAP36 | PTC06 | Human | Thyroid | PTC | 3.92e-13 | 8.74e-01 | 0.2057 |
158763 | ARHGAP36 | PTC07 | Human | Thyroid | PTC | 4.14e-42 | 1.42e+00 | 0.2044 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP36 | SNV | Missense_Mutation | rs745365369 | c.695N>T | p.Ala232Val | p.A232V | Q6ZRI8 | protein_coding | tolerated(0.23) | benign(0.14) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
ARHGAP36 | SNV | Missense_Mutation | c.272N>T | p.Pro91Leu | p.P91L | Q6ZRI8 | protein_coding | tolerated(0.32) | benign(0.189) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ARHGAP36 | SNV | Missense_Mutation | novel | c.713N>C | p.Val238Ala | p.V238A | Q6ZRI8 | protein_coding | deleterious(0.04) | possibly_damaging(0.492) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ARHGAP36 | SNV | Missense_Mutation | c.1169N>C | p.Lys390Thr | p.K390T | Q6ZRI8 | protein_coding | deleterious(0) | benign(0.053) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ARHGAP36 | SNV | Missense_Mutation | novel | c.1085T>C | p.Ile362Thr | p.I362T | Q6ZRI8 | protein_coding | tolerated(0.26) | possibly_damaging(0.824) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARHGAP36 | SNV | Missense_Mutation | c.208N>A | p.Glu70Lys | p.E70K | Q6ZRI8 | protein_coding | tolerated(0.08) | probably_damaging(0.935) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | novel | c.1374N>T | p.Lys458Asn | p.K458N | Q6ZRI8 | protein_coding | deleterious(0.04) | benign(0.06) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARHGAP36 | SNV | Missense_Mutation | rs146720933 | c.446N>A | p.Arg149His | p.R149H | Q6ZRI8 | protein_coding | tolerated(0.2) | probably_damaging(0.976) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ARHGAP36 | SNV | Missense_Mutation | c.688N>T | p.Pro230Ser | p.P230S | Q6ZRI8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | rs370750175 | c.757N>A | p.Ala253Thr | p.A253T | Q6ZRI8 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |